Chronic inflammatory arthritis following checkpoint inhibitor therapy for cancer: game changing implications

Leonard Calabrese¹, Xavier Mariette^{2

3}

Affiliations

¹ Rheumatology/Immunology, Cleveland Clinic, Cleveland, Ohio, USA calabrl@ccf.org.
² Rheumatology, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux universitaires Paris-Sud - Hôpital Bicêtre, Le Kremlin Bicêtre, France.
³ AP-HP Université Paris Saclay, Center for Immunology of Viral Infections and Auto-immune Diseases (IMVA), Institut pour la Santé et la Recherche Médicale (INSERM) UMR 1184, Université Paris-Saclay, Le Kremlin Bicêtre, France.

Editorial

Leonard Calabrese et al. Ann Rheum Dis. 2020 Mar.

. 2020 Mar;79(3):309-311.

doi: 10.1136/annrheumdis-2019-216510. Epub 2020 Jan 3.

Leonard Calabrese¹, Xavier Mariette^{2

3}

¹ Rheumatology/Immunology, Cleveland Clinic, Cleveland, Ohio, USA calabrl@ccf.org.
² Rheumatology, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux universitaires Paris-Sud - Hôpital Bicêtre, Le Kremlin Bicêtre, France.
³ AP-HP Université Paris Saclay, Center for Immunology of Viral Infections and Auto-immune Diseases (IMVA), Institut pour la Santé et la Recherche Médicale (INSERM) UMR 1184, Université Paris-Saclay, Le Kremlin Bicêtre, France.

No abstract available

Keywords: autoimmune diseases; autoimmunity; inflammation.

Conflict of interest statement

Competing interests: None declared.

Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation.
Braaten TJ, Brahmer JR, Forde PM, Le D, Lipson EJ, Naidoo J, Schollenberger M, Zheng L, Bingham CO, Shah AA, Cappelli LC. Braaten TJ, et al. Ann Rheum Dis. 2020 Mar;79(3):332-338. doi: 10.1136/annrheumdis-2019-216109. Epub 2019 Sep 20. Ann Rheum Dis. 2020. PMID: 31540935 Free PMC article.